Nowadays practical antihypertensive therapy involves not only simple normalization of blood pressure but also a reduction of the risks of cardiovascular disease.
The development of new antihypertensive drugs with various mechanisms of action has greatly facilitated the control of blood pressure in hypertensive patients. Therefore, when treating hypertension, more attention should now be directed towards preventing target organ damage, such as arteriosclerosis and cardiac hypertrophy, in an efficient manner, and thereby reduce the incidence of cerebrovascular disease, coronary heart disease, and renal failure. In this respect, the results of recent epidemiological studies (1-3) have raised concern about traditional antihypertensive therapy with diuretics and /9-blockers, since these drugs may not reduce the risk of coronary heart disease, although they substantially reduce that of cerebrovascular disease. Diuretics and /9-blockers are known to adversely affect lipid and glucose metabolism, which may increase the risk of coronary heart disease (4) (5) (6) . Therefore, antihypertensive therapy should be selected after a careful assessment of the overall benefits and risks of treatment, rather than focusing solely on the normalization of blood pressure, to effectively reduce the risks of cardiovascular disease.
While diuretics and /9-blockers may adversely alter lipid and glucose metabolism, a number of studies have indicated that selective a 1-adrenergic receptor blockers improve the lipid profile and glucose tolerance (4) (5) (6) . Therefore, antihypertensive therapy with a1-blockers may prevent cardiovascular diseases associated with arteriosclerosis. However, several points must be further clarified to better understand how a1-blockers affect the metabolism of serum lipids and thereby define their full range of benefits when used for antihypertensive therapy. These points include the long-term effects of a 1-blockers on serum lipids, effectiveness when combined with other antihypertensive or lipid-lowering drugs, and the identification of patients who are most likely to respond to a1-blocker treatment with a decrease in serum lipids.
This multicenter, prospective open-label trial was undertaken to examine the long-term effects of doxazosin, a selective and long-acting a1-blocker, on lipid metabolism in hypertensive patients. Attention was focused on the points listed above. viously untreated, 30 to 74 years of age, were enrolled in the trial. Informed consent was obtained from all subjects. The study was approved by the institutional review board at each hospital. The exclusion criteria were 1) severe target organ damage as a complication of hypertension (cerebrovascular disease, ischemic heart disease, renal failure); 2) the presence of other chronic diseases, such as diabetes mellitus, liver failure, or a history of congestive heart failure; 3) the presence of a secondary cause of hypertension; and 4) other conditions judged by the attending physician to contraindicate the use of the study drug, such as pregnancy or hypersensitivity to ai-receptor blockers. Diabetes mellitus was not diagnosed when the fasting blood glucose was less than 6.6 mmol/l and glycosuria was negative by test-tape (less than 3 mmol/l). Blood pressure was measured by a physician using a mercury manometer with the patient in the sitting position. Regardless of the use of antihypertensive medication, patients were eligible if their systolic pressure was higher than 160 mmHg, their diastolic pressure was higher than 95 mmHg, or both, during a 4-week run-in period. Treatment with doxazosin was begun at a dose of 1 mg once daily, orally. During subsequent visits the dose was titrated within the range of 0.5 to 8 mg per day, so that the sitting blood pressure was maintained under 150/90 mmHg. If the patient was already receiving antihypertensive and/or lipid-lowering drugs, this treatment was not modified during the study period. The patients were examined at 2-to 4-week intervals over 12 months. Patients were withdrawn from the study in the following cases: 1) the development of severe adverse reactions or worsening of symptoms; 2) failure to control blood pressure, even with the maximum dose of doxazosin, and necessity for additional antihypertensive medication; 3) poor compliance with treatment; 4) the development of severe concomitant diseases.
Besides monitoring blood pressure, pulse rate, and clinical condition at each visit, laboratory tests were performed before treatment and 3, 6, and 12 months after the initiation of treatment. The laboratory tests included urinalysis, blood cell counts, and fasting blood aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase, ` blood urea nitrogen, creatinine, uric acid, sodium, potassium, chloride, glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. Aspartate aminotransferase and alanine aminotransferase are expressd in Karmen units (KU), and alkaline phosphatase and lactate dehydrogenase in international units (IU). Blood samples were drawn from an antecubital vein in the morning after an overnight fast. Low-density lipoprotein (LDL) cholesterol was calculated according to Friedewald's formula (7): LDL cholesterol = total cholesterol -(HDL cholesterol + 1/5 triglycerides) Data are given as the mean ± SD. Time-course changes in variables were evaluated by analysis of variance for repeated measures. A p value less than Icance.
Results
A total of 253 patients met the inclusion criteria and were enrolled. Of these patients, 10 moved during the study period and were thus withdrawn. Three patients were excluded from data analysis because of poor compliance. Eleven patients decided not to visit the hospital due to personal reasons; however, follow-up inquiry by telephone revealed that all were doing well. Administration of doxazosin was stopped in 3 patients because of normalization of blood pressure. Conversely, in another 3 patients, additional antihypertensive medication was needed to control blood pressure. Doxazosin was discontinued in 13 patients because of side effects (palpitation, 4 patients; headache, 3; orthostatic hypotension, 2; dizziness, 2; malaise, 2). These side effects were mostly related to a reduction in blood pressure or were typical of a1-receptor blockers. In total, 43 patients were excluded from data analysis. Table 1 summarizes the baseline characteristics of the 210 patients who completed the study. Thirtyseven patients had a body mass index greater than 26 kg/m2 and were considered obese. According to the World Health Organization (WHO) criteria for organ damage, 121 patients were classified as stage I and the remaining 89 as stage II. Figure 1 shows the changes in blood pressure and pulse rate during the study period. Averaged blood pressure was effectively lowered below 150/90 mmHg one month after starting doxazosin. This antihypertensive effect was well maintained throughout the study period. The average maintenance dose was approximately 2 mg/d. The pulse rate did not increase during the study period.
Coefficients of variation for serum lipids of standard samples measured at seven main laboratories were 4.1% for total cholesterol, 6.4% for HDLcholesterol, and 5.1% for triglycerides. These values were comparable to the intra-assay variation (total cholesterol 2.0%, HDL-cholesterol 6.4%, and triglycerides 4.6%) and the inter-assay variation (total cholesterol 3.7%, HDL-cholesterol 7.1%, and Table 2 lists the changes in serum lipids during doxazosin treatment. Total cholesterol and LDL-cholesterol were significantly reduced after starting doxazosin. These reductions persisted even after 1 year of doxazosin therapy. On the other hand, the changes in HDL-cholesterol and triglycerides were not significant. The patients were divided into 2 groups according to their baseline serum level of total cholesterol to see if doxazosin lowered serum lipids in hypertensive patients with hypercholesterolemia. Fifty-nine patients were assigned to the high-cholesterol group (>_ 5.7 mmol/l) and 151 to the normal-cholesterol group ( < 5.7 mmol/l). As shown in Table 3 , the reduction in total and LDL-cholesterol levels was more prominent in the high-cholesterol group than in the normal-cholesterol group. Changes failed to reach statistical significance in the normal cholester- armn g the study period in 2.10 hypertensive patients treated Of the hyperlipidemic patients included in the study, 20 were receiving lipid-lowering drugs (LLD): 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in 17 patients, and clofibrate, nicotinic acid, or probucol in 1 patient each). Table 4 shows the changes in serum total and LDL-cholesterol levels in these patients and in 190 patients who did not take LLD. Total cholesterol and LDL-cholesterol were significantly reduced in patients concurrently receiving LLD as well as in patients not receiving such drugs.
Of the 210 hypertensive patients analyzed, 106 were previously or concurrently treated with other antihypertensive drugs. Diuretics were given to 19 patients, j9-blockers to 30, calcium entry blockers to 62, and angiotensin-converting enzyme inhibitors to 34. Twenty-eight patients were treated with two or more antihypertensive drugs besides doxazosin. Figures 2 and 3 long-term treatment with doxazosin, either alone or in combination with other antihypertensive drugs, was effective in the management of essential hypertension. Intolerable side effects occurred in only a few patients. The dropout rate was comparable to that reported in earlier long-term studies of a 1-blockers (8, 9) . The results of the present study provide further evidence that doxazosin is an effective and well tolerated antihypertensive drug. Furthermore, as reported previously (10-13), doxazosin significantly lowered serum total cholesterol and LDL-cholesterol. A number of earlier studies have also reported an increase in HDL-cholesterol associated with a1-blocker therapy; there was no such increase in the present study. Lack of a consistent effect of as-blockers on HDL-cholesterol in the earlier studies (4, 10, 12, 14) may indicate that these drugs have a smaller effect on HDL-cholesterol than on LDL-cholesterol. In contrast to a 1-blockers, diuretics are known to increase serum LDL-cholesterol and triglyceride levels (4, 5) . However, it is not clear whether elevated levels persist after years of treatment with diuretics (15, 16) . In the present study, the lipidlowering effect of doxazosin was maintained throughout the 1-year treatment period. Moreover, this effect was especially remarkable in hypertensive patients with hypercholesterolemia, who have an increased risk of coronary heart disease. Thus, besides lowering blood pressure, chronic doxazosin therapy is expected to improve hypercholesterolemia in hypertensive patients. Since both hypertension and hypercholesterolemia are major risk factors for coronary heart disease, antihypertensive therapy with doxazosin may provide substantial benefits to hypertensive patients.
In the present study, doxazosin reduced serum cholesterol levels even in hypertensive patients who were already receiving lipid-lowering drugs or were prescribed such drugs concurrently with doxazosin. Therefore, the effects of doxazosin on serum lipids are thought to be additional to those of lipid-lowering drugs. This should be borne in mind when treating hypertensive patients who also have hyperlipidemia. Moreover, this study demonstrated that doxazosin lowers serum lipid concentrations even when given concurrently with other antihypertensive drugs, including diuretics. Diuretics may adversely alter lipid and glucose metabolism, and this may constitute an additional risk of cardiovascular disease in hypertensive patients (1-6). However, diuretics are often an essential element of antihypertensive therapy, because most other antihypertensive drugs cause sodium retention, which blunts their hypotensive efficacy. Diuretics improve this unfavorable state and augment the hypotensive effect of other concurrently used antihypertensive drugs. Some studies have reported an increase in insulin sensitivity with a1-blockers (17, 18) . Combination therapy with a1-blockers and diuretics may therefore be therapeutically useful in hypertensive patients. Alphas-blockers offset the adverse effects of diuretics on lipid and glucose metabolism, and diuretics augment the hypotensive effect of a1-blocker's.
With regard to the mechanisms involved in the lipid-lowering effect of a1-blockers, several possibilities have been proposed. First, it has been reported that a1-blockers suppress HMG-CoA reductase, a rate-limiting enzyme in cholesterol biosynthesis, in (11) . Increased lipoprotein lipase activity promotes the catabolism of very-low-density lipoprotein triglycerides and causes an inverse increase in HDLcholesterol. Our study does not provide much information regarding the mechanisms involved in the lipid-lowering effect of doxazosin. However, since doxazosin did not affect the serum HDL-cholesterol level in the present study, the third possibility, that is, an increase in lipoprotein lipase activity, does not seem compatible with the results of this study. The first possibility, suppression of HMG-CoA reductase, is also unlikely because the lipid-lowering effect of doxazosin was not blunted even when other lipid-lowering drugs, mainly HMG-CoA reductase inhibitors, were used concurrently.
Hypertension is often associated with glucose intolerance and dyslipidemia. Therefore, these disorders may arise from a common predisposition, i.e., insulin resistance (21) (22) (23) . Because all these disorders promote atherosclerosis and the occurrence of cardiovascular disease, it is important, when treating hypertension, to take each of them into consideration to reduce the overall risk of cardiovascular disease. Accumulating evidence, including the results of this study, suggests that a l-blockers not only lower blood pressure but also improve lipid and glucose metabolism and insulin resistance (4) (5) (6) 24 ). In addition, al-blockers have been shown to possess a pharmacological basis for inhibiting cardiac hypertrophy by a mechanism that is not mediated by blood pressure reduction (25, 26). Thus, aiblockers may prevent cardiovascular complications in hypertensive patients by multiple mechanisms. At present, however, only diuretics and R-blockers have been demonstrated to substantially reduce the incidence of cardiovascular disease. An epidemiological study involving a large population is awaited to confirm the preventive effect of al-blockers against cardiovascular diseases in hypertensive patients.
The present study demonstrates that the lipidlowering effect of doxazosin is long-lasting, is especially remarkable in patients with hypercholesterolemia, and is independent. of concurrent antihypertensive or lipid-lowering drugs. These findings are meaningful for physicians who treat hypertension with a l-blockers to reduce the overall risk of cardiovascular disease. 
